Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Second-generation gene therapy for prion diseases
EF 2024-25
Résumé
Prion disorders are fatal neurodegenerative diseases in mammals, causing the death of one in 5,000 people. They arise when the normal cellular prion protein (PrPC) found in most vertebrate cells acquires an abnormal fold referred to as PrPSc, either spontaneously or through a mutation. Once formed or introduced through ingestion or medical procedures, PrPSc induces additional PrPC to convert to the abnormal PrPSc -fold, thereby spreading the disease throughout the brain, causing cell death and the formation of sponge-like holes.Studies in mice have shown that reducing PrPC levels extends survival profoundly by slowing the conversion to PrPSc. Additionally, animals with ablated prion genes remain healthy, indicating that lowering PrPC levels is safe. Recent advances in gene-editing, particularly CRISPR-Cas technology, may offer a solution. I hypothesize that this technology can be harnessed for a bespoke gene therapy for prion diseases. To this end, I will insert the necessary components into a non-pathogenic shell, derived from adeno-associated virus (AAV) vectors. I will optimize these vectors for delivery to brain cells known to produce PrPC most actively. Next, I will quantify how well this system ablates the prion gene, initially in brain-like cells in the dish, before moving to studies in mice. If this pre-clinical program is successful, it may not take long before it can enter compassionate use trials because no other therapy exists for these devastating diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529901
Name
Krishnan Medha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Second-generation gene therapy for prion diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr Cas-9; Gene Therapy; Neurodegeneration; Prion Disease; Prion Protein
Abstract
Prion disorders are fatal neurodegenerative diseases in mammals, causing the death of one in 5,000 people. They arise when the normal cellular prion protein (PrPC) found in most vertebrate cells acquires an abnormal fold referred to as PrPSc, either spontaneously or through a mutation. Once formed or introduced through ingestion or medical procedures, PrPSc induces additional PrPC to convert to the abnormal PrPSc -fold, thereby spreading the disease throughout the brain, causing cell death and the formation of sponge-like holes.Studies in mice have shown that reducing PrPC levels extends survival profoundly by slowing the conversion to PrPSc. Additionally, animals with ablated prion genes remain healthy, indicating that lowering PrPC levels is safe. Recent advances in gene-editing, particularly CRISPR-Cas technology, may offer a solution. I hypothesize that this technology can be harnessed for a bespoke gene therapy for prion diseases. To this end, I will insert the necessary components into a non-pathogenic shell, derived from adeno-associated virus (AAV) vectors. I will optimize these vectors for delivery to brain cells known to produce PrPC most actively. Next, I will quantify how well this system ablates the prion gene, initially in brain-like cells in the dish, before moving to studies in mice. If this pre-clinical program is successful, it may not take long before it can enter compassionate use trials because no other therapy exists for these devastating diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Krishnan, Medha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~